We help keep patients, caregivers, and medical professionals informed about the latest happenings at the Brigham and Women’s Hospital Heart & Vascular Center through newsletters, press releases, our annual report, and other media. Below is a list of our recent heart and vascular news stories.
At the Heart of the Future is our annual report on the innovative care and research taking place here at the Heart & Vascular Center. Read At the Heart of the Future 2016 report, or At the Heart of the Future 2015 report.
Our Heart & Vascular Center Update newsletters provide detailed updates on what’s happening at the Center, including case studies of new procedures and descriptions of new programs. Read current issue and past issues of Heart & Vascular Center Update.
Calum MacRae, MD, PhD, Chief, Division of Cardiovascular Medicine at BWH, and an international team of collaborators have been selected to receive the One Brave Idea Research Award, a five year, $75 million award from the American Heart Association, Verily Life Sciences and AstraZeneca.
Study pinpoints identifies four factors that may account for sex differences in statin therapy among patients with coronary artery disease (CAD).
Study shows cangrelor reduces the odds of cardiovascular events by 35 Percent in women undergoing coronary stenting when compared to standard therapy
Researchers plan to conduct a large-scale study testing the impact of triglyceride reduction on cardiovascular event rates
Nationwide study of women reveals that those with diabetes are most susceptible to the adverse cardiovascular risks posed by exposure to air pollution.
A marker commonly used to determine if a patient is having a heart attack can also be used to identify stable patients at high risk for deadly cardiac events, according to a new study.
Trial by BWH researchers is the first to report on the cardiovascular safety of widely prescribed glucose-lowering drug.
New insights into blood vessel metabolism may have major implications for diagnosis, treatment, and prevention.
Patients who received the experimental therapy were half as likely to experience adverse cardiovascular outcomes as compared to those who received standard care.
New research finds that ticagrelor use beyond one year reduces the risk of further cardiovascular events.
For over a century, a leader in patient care, medical education and research, with expertise in virtually every specialty of medicine and surgery.